Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01862289
Other study ID # P110904
Secondary ID CRC 11093
Status Completed
Phase N/A
First received
Last updated
Start date April 28, 2013
Est. completion date October 18, 2016

Study information

Verified date April 2018
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Most of asthmatics patients remain uncontrolled despite an inhaled steroids treatment. Chronic hyperventilation syndrome (also called Idiopathic Hyperventilation) occurs in 20 to 40% of asthmatic patients. The purpose of the study is to assess the prevalence of chronic hyperventilation syndrome in a specific population of difficult-to-treat asthmatics patients, those who receive daily high doses of inhaled steroids (≥ 1000 µg of fluticasone with an additional treatment by a long-acting beta 2-agonist (LABA) and who remain uncontrolled (Asthma control test (ACT) < 18). We plan to realize a systematic assessment of the diagnosis of chronic hyperventilation syndrome with the Nijmegen questionnaire, blood gases at rest, hyperventilation testing and Cardiopulmonary Exercise Testing(CPET). We also will collect demographic information as well as information about asthma history, asthma control and treatment.


Description:

There is only one visit. During this visit, each patient will complete self-questionnaires like Nijmegen, Hospital Anxiety and Depression Scale(HAD), Short-Form 36(SF36), and Asthma Quality of Life Questionnaire (AQLQ), The participants will have baseline spirometry and fractional exhaled nitric oxide measured at expiratory flow of 50 mL/s (FENO50), blood gases at rest, an hyperventilation challenge and Cardiopulmonary Exercise Testing(CPET) to determine accurately the presence or not of chronic hyperventilation syndrome. The diagnosis is confirmed by two positive tests (Nijmegen, Hyperventilation challenge and blood gases) and the final decision of a medical committee. The first step is to determine the prevalence oh this syndrome in this specific population. The second step is to assess the sensitivity, the specificity, the false positive rate and the false negative rate of the different parameters measured during the tests.


Recruitment information / eligibility

Status Completed
Enrollment 151
Est. completion date October 18, 2016
Est. primary completion date October 18, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- men and women,

- aged more than 18,

- non smokers for two years or longer, less than 10 pack/years smoking history,

- physician-diagnosed asthma,

- uncontrolled asthma with Asthma control test (ACT) < 18,

- historical of FEV1 reversibility,

- daily inhaled steroids treatment by at least 2000microg eq beclomethasone,

- Forced expiratory volume in 1 second (FEV1) > 50% predicted value

Exclusion Criteria:

- other chronic pulmonary disease,

- vocal cord dysfunction,

- pregnancy,

- Participation in another interventional research trial,

- unable to provide consent,

- asthma exacerbation within the last 4 weeks

Study Design


Intervention

Other:
Diagnostic of chronic hyperventilation syndrome
Nijmegen questionnaire, Hyperventilation challenge and blood gases

Locations

Country Name City State
France Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital Le Kremlin-bicetre

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic of the hyperventilation syndrome value of Nijmegen questionnaire, of blood gases at rest, of hyperventilation testing and of CPET Up to 4 hours
Secondary Assess the diagnosis value of the nijmegen questionnaire. Up to 4 hours
Secondary Assess the diagnosis value of the blod gases at rest. up to 4 hours
Secondary Assess the diagnosis value of the hyperventilation challenge. Up to 4 hours
Secondary Assess the diagnosis value of the CPET. Up to 4 hours
See also
  Status Clinical Trial Phase
Terminated NCT01197482 - Inhaled Steroids and Control of Severe Asthma
Withdrawn NCT02952066 - Expressions of TRPV1 in Airway of Asthmatics N/A
Completed NCT02559791 - Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Phase 2/Phase 3
Recruiting NCT03617718 - Project 2 Airway Potential Hydrogen (pH) in Asthma Phase 1/Phase 2
Recruiting NCT01839591 - Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa N/A
Withdrawn NCT00954850 - A National Program for Severe Asthma: The Canadian Severe Asthma Network N/A
Completed NCT01748175 - Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma
Withdrawn NCT01745809 - Bronchoscopy Study for Severe Asthma N/A
Completed NCT02717689 - A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma N/A
Completed NCT01750411 - Severe Asthma Research Program - Wake Forest University
Completed NCT02659618 - Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma
Withdrawn NCT00689806 - Evaluation of Lovastatin in Severe Persistent Asthma Phase 1/Phase 2